Cambridge Investment Research Advisors
NAVB

Cambridge Investment Research Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Cambridge Investment Research Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,905
Closed -$16K – 2422
2019
Q1 		$16K Sell
5,905
-32
-0.5% -$94 ﹤0.01% 2260
2018
Q4 		$12K Buy
5,937
+32
+0.5% +$132 ﹤0.01% 2135
2018
Q3 		$27K Hold
5,905
– – ﹤0.01% 2217
2018
Q2 		$27K Buy
5,905
+86
+1% +$450 ﹤0.01% 2183
2018
Q1 		$42K Buy
5,819
+270
+5% +$2.02K ﹤0.01% 2108
2017
Q4 		$40K Buy
5,549
+3,911
+239% +$33.1K ﹤0.01% 2073
2017
Q3 		$14K Sell
1,638
-3
-0.2% -$25 ﹤0.01% 1990
2017
Q2 		$17K Buy
1,641
+3
+0.2% +$30 ﹤0.01% 1916
2017
Q1 		$19K Buy
1,638
+250
+18% +$2.84K ﹤0.01% 1756
2016
Q4 		$18K Buy
1,388
+200
+17% +$3.17K ﹤0.01% 1655
2016
Q3 		$22K Buy
1,188
+350
+42% +$4.43K ﹤0.01% 1724
2016
Q2 		$9K Buy
+838
New +$16.5K ﹤0.01% 1550

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cambridge Investment Research Advisors's NAVB Position: Q2 2019 in Review

Cambridge Investment Research Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2019, closing a stake of 5,905 shares — an estimated $16K sold.

Cambridge Investment Research Advisors first reported a position in NAVB in Q2 2016 and held it in 12 quarters. The position peaked at $42K in Q1 2018. 27 funds tracked by Wall St. Rank hold NAVB as of Q2 2019.

  • Cambridge Investment Research Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2019 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 5,905 Navidea Biopharmaceuticals Inc. shares in Q2 2019, an estimated $16K.
  • Cambridge Investment Research Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2016 and held it in 12 quarters.
  • Cambridge Investment Research Advisors's Navidea Biopharmaceuticals Inc. position peaked at $42K in Q1 2018.
  • 27 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2019.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2019, filed 15 Aug 2019.